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Objective: Most investigations of pharmacotherapy for treating Alzheimer's disease focus on patients
with mild-to-moderate symptoms, with little evidence to guide clinical decisions when symptoms be-
come severe. We examined whether continuing donepezil, or commencing memantine, is cost-
effective for community-dwelling, moderate-to-severe Alzheimer's disease patients.
Methods:Cost-effectiveness analysis was based on a 52-week,multicentre, double-blind, placebo-controlled,
factorial clinical trial. A total of 295 community-dwelling patients withmoderate/severe Alzheimer's disease,
already treated with donepezil, were randomised to: (i) continue donepezil; (ii) discontinue donepezil; (iii)
discontinue donepezil and start memantine; or (iv) continue donepezil and start memantine.
Results: Continuing donepezil for 52weeks was more cost-effective than discontinuation, considering
cognition, activities of daily living and health-related quality of life. Starting memantine was more
cost-effective than donepezil discontinuation. Donepezil–memantine combined is not more cost-
effective than donepezil alone.
Conclusions: Robust evidence is now available to inform clinical decisions and commissioning strategies so
as to improve patients' lives whilst making efﬁcient use of available resources. Clinical guidelines for treating
moderate/severe Alzheimer's disease, such as those issued byNICE in England andWales, should be revisited.
# 2016 The Authors. International Journal of Geriatric Psychiatry published by John Wiley & Sons Ltd.
Key words: Alzheimer's disease; donepezil; memantine; cost-effectiveness
History: Received 19 May 2016; Accepted 25 August 2016; Published online in Wiley Online Library (wileyonlinelibrary.com)
DOI: 10.1002/gps.4583
# 2016 The Authors. International Journal of Geriatric Psychiatry published by John Wiley & Sons Ltd. Int J Geriatr Psychiatry 2016
RESEARCH ARTICLE
This is an open access article under the terms of the Creative Commons Attribution License, which permits use, distribution and reproduction
in any medium, provided the original work is properly cited.
Introduction
Understanding the resource consequences of demen-
tia treatments is particularly pertinent given
projected increases in prevalence (Prince et al.,
2015) and associated expenditure (Comas-Herrera
et al., 2007). Treatment decisions are increasingly
informed by guidelines from bodies such as The
National Institute for Health and Care Excellence
(NICE), built on both clinical and cost-effectiveness
evidence. In 2009, NICE revised its guidance on
acetylcholinesterase (AChE) inhibitor treatment of
patients with moderate dementia, recommending
that treatment should stop at the severe stage.
Following new economic modelling, The National
Institute for Clinical Excellence (2011) revised its
guidance, allowing use of drugs within their licensed
indications. A review of more recent evidence led to
slightly updated guidance on medication treatment,
with the three AChE inhibitors (donepezil, galanta-
mine and rivastigmine) recommended as options
for managing mild-to-moderate Alzheimer's disease
(AD) and memantine recommended as an option
for people with moderate AD who are intolerant of
or have a contraindication to AChE inhibitors or
with severe AD (National Institute for Health and
Care Excellence 2016).
There remains little evidence to guide clinical
decision-making when patients reach moderate-to-
severe AD. We therefore sought to examine the clini-
cal and cost-effectiveness consequences of continu-
ing donepezil and commencing memantine (singly
or in combination with donepezil). Clinical effec-
tiveness ﬁndings have been published (Howard
et al., 2012); here, we examine the cost-effectiveness
consequences.
Method
Participants
Patients met standardised clinical criteria for
probable/possible moderate or severe AD (McKhann
et al., 1984) and had been continuously prescribed
donepezil for >3months. Their prescribing clinician
was considering change ofmedication, based on discus-
sionswith patient and carer,NICE guidance and clinical
judgement. Patients had sMMSE score of 5–13 (Molloy
and Standish, 1997), were community-living and had a
carer who was co-resident or visited at least daily. Pa-
tients were recruited from 15NHS English and Scottish
centres between February 2008 and March 2010.
Design
DOMINO-AD was a multicentre, double-blind,
placebo-controlled, factorial (2×2) clinical trial, with
assessment of outcomes and costs over 52weeks. It
compared four treatments: (i) continue donepezil
10mg per day with placebo memantine; (ii) discon-
tinue donepezil (following 4weeks donepezil 5mg)
with placebo memantine; (iii) discontinue donepezil
and initiate memantine 20mg per day; and (iv) con-
tinue donepezil 10mg per day and initiate memantine
20mg per day. Tablets were provided by the manufac-
turers. The study protocol was published before any
data analysis (Jones et al., 2009).
Ethics
DOMINO-ADwas registered with the ISRCTNRegistry
(ISRCTN49545035). Ethical approval was received from
Scotland ‘A’ Multicentre Research Ethics Committee.
An Independent Data Monitoring Committee
reviewed efﬁcacy and safety data every 6months.
Randomisation
A prepared unrestricted randomised list of assign-
ments was used for the ﬁrst 80 participants to ensure
allocation concealment. Subsequent participants were
randomly assigned to one of four treatment groups
by the MRC CTU using randomised minimisation.
Groups were stratiﬁed by centre, duration of donepezil
treatment before entry (3–6months; >6months),
baseline sMMSE score (5–9; 10–13) and age (<60;
60–74; >74 years). Patients, caregivers, clinicians,
outcome assessors and investigators were blinded to
assignment.
Outcomes
Patients were assessed at baseline (pre-randomiza-
tion), at week 6 post-randomisation to assess short-
term effects of donepezil withdrawal, and at weeks
18, 30 and 52.
Primary outcomes were:
• cognition: sMMSE (range 0–30, higher scores indi-
cate better cognitive function) rated by treating
clinicians;
• functioning in activities of daily living: Bristol
Activities of Daily Living Scale (BADLS) (Bucks
et al., 1996) (range 0–60, higher scores indicate
greater functional impairment) rated by carers.
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• Secondary outcomes were:
• behavioural and psychological symptoms: Neuro-
psychiatric Inventory (NPI) (Cummings et al.,
1994) (range 0–144, higher scores indicate more
symptoms) rated by treating clinicians;
• dementia-speciﬁc health-related quality of life:
DEMQOL-Proxy (Smith et al., 2007) (range
31–134, higher scores indicate better quality of life)
rated by carers;
• generic health-related quality of life: EQ-5D-3L
(EuroQol Group, 1990) rated by carers;
• health status of family or other unpaid carers:
General Health Questionnaire (GHQ-12) (Gold-
berg et al., 1997) (range 0–12, higher scores
indicate increased psychological morbidity).
The economic evaluation focused on three out-
comes: sMMSE, BADLS, EQ-5D-3L. We applied
societal weights to EQ-5D-3L (Dolan et al., 1995) to cal-
culate utility values.Quality-adjusted life years (QALYs)
were calculated by ‘area-under-the-curve’ analysis,
with linear interpolation between assessment points.
Before commencing data analysis, and based on the
ﬁrst 127 participants to complete DOMINO-AD, the
research team published values for minimum clini-
cally important differences on sMMSE (1.4 points),
BADLS (3.5 points) and NPI (8 points), based upon
0.4 standard deviations of changes from baseline
(Howard et al., 2011).
Sample size
Original planned sample size was 800, adjusted to 430
based on standard deviations of outcomes from a blinded
analysis of accrued data. Allowing for expected 20%
missing visits, at two-sided signiﬁcance level of 5%,
n=430 would give 95% power to detect a 1.0 point
sMMSE difference and 90% power to detect a 2.0 point
BADLS difference between donepezil and placebo, or be-
tween memantine and placebo, at 52weeks, and 96%
power to detect a 1.5 point sMMSE difference, and 80%
power to detect a 2.5 point BADLS difference between
combination treatment and monotherapy at 52weeks.
Costs
Data on services and unpaid support were collected
for each patient at:
• baseline (randomisation) for a retrospective period
of 13weeks;
• 6-week post-randomisation assessment retrospec-
tively over 6weeks;
• 30-week assessment retrospectively over 24weeks;
• 52-week assessment retrospectively over 22weeks.
Services and support data for patients were recorded
on the Client Service Receipt Inventory (CSRI)
(Beecham & Knapp, 2001) completed by family or
professional carers, covering: inpatient stays, out-
patient attendances, day hospital, social clubs, lunch
clubs, day care, community-based professional contacts
(e.g. psychologists, psychiatrists, GPs, nurses, social
workers, occupational therapists, home care) and all
other services. Costs were assumed to be incurred by
health and social care agencies even though some indi-
viduals make co-payments. Data were also collected
on volunteer support, befriending, telephone care-line
support and unpaid support by family and friends.
Unit costs reﬂecting long-run marginal opportu-
nity costs were drawn from available public sources,
set at 2013/14 prices. Costs per unit of measurement
for each service type (e.g. per contact with health
professional) were mainly taken from Curtis (2014);
NHS Reference Costs (Department of Health, 2014)
were used for inpatient and outpatient attendances.
Costs of unpaid care were estimated from informa-
tion on volume and type of support, the opportunity
cost of lost work (wage rate) for carers in paid
employment and replacement cost for those not in
paid employment based on cost of a home care
worker (Curtis, 2014).
Medication costs were applied over the treatment ti-
tration andmaintenance schedules. Donepezil came off
patent in 2012 and memantine in 2014; we attached
prices obtained from pharmacies at study sites for the
generic versions (4p per 5-mg tablet and 6p per 10-
mg tablet of donepezil; 4p per 10-mg tablet and 7p
per 20-mg tablet for memantine). (At the time of the
trial, both donepezil and memantine were under pat-
ent; donepezil prices were £2.27 per 5-mg tablet and
£3.18 per 10-mg tablet, and memantine prices were
£1.23 per 10-mg tablet and £2.46 per 20-mg tablet.
However, we use only generic prices in our analyses)
Cost-effectiveness
Research questions were: (i) is donepezil continuation
more cost-effective than donepezil discontinuation
over 52weeks; (ii) is memantine, singly or in combi-
nation with donepezil, more cost-effective than
memantine placebo; and (iii) is the combination of
donepezil and memantine more cost-effective than
donepezil alone.
Primary cost-effectiveness analyses were conducted
from a health and social care perspective. Cost
Donepezil and memantine cost-effectiveness
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subtotals were also calculated: trial medication costs;
hospital costs (inpatient, outpatient, accident and
emergency); and community-based health, social and
primary care. In sensitivity analyses, we adopted a
societal perspective, adding unpaid care costs to health
and social care service costs.
BADLS, SMMSE and QALYs were used, in turn,
as measures of effectiveness in the cost-effectiveness
analyses.
Statistical analysis
Analyses were conducted on participants receiving at
least one dose of trial medication (including placebo),
applying intention-to-treat principles as far as practi-
cably possible, given missing data. Participants were
analysed in groups to which they were allocated irre-
spective of treatment discontinuation or open-label
treatment. All non-missing scores at every visit
(irrespective of whether patients were still on trial
medication or switched to open-label treatment) were
included; there was no imputation of missing scores.
Full details of outcome analyses are given elsewhere
(Howard et al., 2012).
Cost data were analysed by regressing 52-week
health and social care costs (or societal costs in
secondary analyses) on treatment allocation, centre,
age at baseline, duration of donepezil treatment pre-
randomisation, baseline sMMSE and total health and
social care costs (or societal costs) in the 13-week
pre-randomisation period. To mitigate effects of data
skewness, non-parametric bootstrapping was used to
estimate 95% conﬁdence intervals (CIs) for mean
costs. Where bias-corrected 95% CIs of between-
group change scores excluded zero, they were judged
signiﬁcant at p=<0 · 05.
The cost-effectiveness of one treatment over an-
other was compared by calculating incremental cost-
effectiveness ratios (ICERs), deﬁned as difference in
mean costs divided by difference in mean effects. If
one treatment had lower costs and better outcome
than its comparator it was considered dominant. Difﬁ-
culties arise when one treatment is both more effective
and more costly than its comparator, leaving the
decision-maker to consider whether higher costs are
justiﬁed by better outcomes. Cost-effectiveness accept-
ability curves (CEAC) (van Hout et al., 1994) were
plotted for each cost-outcome combination to show
the likelihood of one treatment being seen as cost-
effective relative to another for a range of (implicit)
values placed on incremental outcome improvements.
Using the net beneﬁt approach, monetary values of
incremental effects and incremental costs were com-
bined, and net beneﬁt (NB) derived as:
NB ¼ λ  effectb  effectað Þ – costb– costað Þ:
λ is willingness-to-pay for a unit improvement in
effectiveness (sMMSE, BADLS, QALYs), and a and b
denote placebo and active treatment, respectively. A
plausible range of λ values was explored for each
outcome. This approach allows costs and outcomes
to be considered on the same monetary scale, taking
account of sampling uncertainty and adjusting for
baseline covariates.
Analyses were undertaken using STATA (version
11) and SPSS 17.
Sensitivity analysis
We explored consequences for cost-effectiveness of
adopting a societal rather than health and social care
perspective.
Results
Sample
A total of 295 participants were recruited. Baseline
characteristics were broadly comparable across treat-
ments (Table 1). At baseline, full service use data and
calculated costs were available for 291 (98.6%) partic-
ipants (73 donepezil alone, 74 memantine alone, 72
donepezil–memantine combined, 72 placebo). By
52weeks, health and social care cost data were avail-
able for 218 (73.9%) participants, and for all data
collection points for 215 (72.9%). At 52weeks, data
on unpaid care were available for 186 (63.1%) partic-
ipants and for all data collection points for 183
(62.0%). Thirty-nine patients died over the trial
period, one lost to follow-up and 29 withdrew. Unless
noted otherwise, analyses from a health and social care
perspective are based on 215 individuals, and analyses
from a societal perspective on 183.
Outcomes
Effectiveness scores in Table 2 are not adjusted for
baseline characteristics/centre; we do make adjust-
ments for the cost-effectiveness analyses below. How-
ard et al. (2012) detail the outcome analyses, where
there was adjustment for the same variables except
for pre-randomisation costs. Additionally adjusting
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for this cost covariate very slightly changes some
numerical values for differences between treatments
but does not change conclusions about relative
effectiveness.
Compared to patients randomised to donepezil dis-
continuation, those continuing on donepezil had
higher sMMSE scores (mean 1.7 points; 95% CI 0.5
to 2.8) and lower BADLS scores (2.9 points; 95%
CI 5.3 to 0.5). In other words, adjusted comparisons
suggest that both cognitive and functional impairment
deteriorated less for patients remaining on donepezil
compared to those who stopped. There was a greater
QALY gain for the donepezil group compared to
placebo (mean 0.11; 95% CI 0.02 to 0.20).
Compared to patients randomised to memantine
placebo, those given memantine had higher sMMSE
scores (mean 1.0 points; 95% CI 0.1 to 2.0) and
slightly lower BADLS scores (1.7 points; 95% CI
3.9 to 0.6), after adjustment for baseline covariates.
There was no difference in QALY gain between these
two groups (0.07; 95% CI 0.02 to 0.16).
The differences between treatment with donepezil
alone and treatment with donepezil and memantine
combined were not statistically signiﬁcant after adjust-
ment for covariates, in terms of sMMSE (mean 0.3
points; 95% CI 1.4 to 2.0), BADLS (1.1 points;
95% CI 7.2 to 5.1) or QALY gain (0.02; 95% CI
0.19 to 0.22).
Costs
Unadjusted health and social care costs were highest
for people with placebo (£7964) and lowest for those
Table 1 Baseline participant characteristics by treatment arm
Donepezil
alone Placebo
Memantine
alone
Donepezil plus
memantine
Total entered in trial 73 73 76 73
Age in years/Mean 77.2 77.7 76.2 77.5
Gender; n (%) Male 22 (30%) 26 (36%) 30 (39%) 24 (33%)
Previous duration of donepezil 3–6months 3 (4%) 3 (4%) 4 (5%) 4 (5%)
>6months 70 (96%) 70 (96%) 72 (95%) 69 (95%)
Standardised Mini-Mental State Examination
(sMMSE)
Mean (sd) 9.0 (2.8) 9.1 (2.4) 9.2 (2.5) 9.1 (2.6)
Bristol Activities of Daily Living Scale (BADLS) Mean (sd) 28.2 (9.0) 28.6 (8.9) 27.1 (9.0) 26.9 (9.8)
Neuropsychiatric Inventory (NPI) Mean (sd) 22.3 (16.7) 22.9 (17.0) 23.1 (16.2) 20.3 (14.4)
DEMQOL-Proxy Mean (sd) 98.3 (13.5) 101.4 (11.7) 96.5 (15.3) 98.3 (13.5)
General Health Questionnaire (GHQ-12) Mean (sd) 2.3 (2.3) 2.8 (3.1) 3.1 (3.1) 1.8 (2.3)
EQ-5D utility Mean (sd) 0.57 (0.28) 0.55 (0.28) 0.59 (0.27) 0.55 (0.29)
Table 2 Clinical and quality of life measure scores (unadjusted for baseline characteristics) over time
Donepezil alone Placebo Memantine alone
Donepezil plus
memantine
Mean (sd) Mean (sd) Mean (sd) Mean (sd)
BADLS
Week 6 29 (9) 32 (9) 28 (9) 28 (10)
Week 18 31 (11) 37 (9) 33 (9) 30 (10)
Week 30 33 (11) 38 (9) 34 (11) 31 (10)
Week 52 37 (11) 41 (9) 37 (10) 35 (9)
sMMSE
Week 6 9 (4) 8 (4) 9 (4) 10 (4)
Week 18 8 (4) 5 (4) 8 (4) 9 (5)
Week 30 6 (4) 5 (4) 6 (4) 8 (5)
Week 52 5 (5) 3 (3) 5 (5) 6 (4)
Generic quality
of life (EQ-5D utility)
Week 6 0.56 (0.28) 0.48 (0.28) 0.61 (0.26) 0.57 (0.28)
Week 18 0.52 (0.30) 0.40 (0.30) 0.52 (0.30) 0.56 (0.26)
Week 30 0.51 (0.32) 0.37 (0.29) 0.46 (0.29) 0.55 (0.26)
Week 52 0.48 (0.31) 0.26 (0.27) 0.42 (0.28) 0.49 (0.32)
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with memantine alone (£4864); for people with
donepezil–memantine combined, cost was £5892,
and for donepezil alone £5418 (Table 3).
Unpaid care costs exceeded health and social care
costs (Table 4). Societal costs were highest for people
with memantine alone (£19969), and lowest for those
with donepezil–memantine combined (£16058).
Comparisons between these mean values should be
tentative as they are not adjusted for baseline charac-
teristics or centre.
We compared costs for patients allocated to each
treatment after adjusting for centre, age at baseline,
duration on donepezil pre-randomisation, sMMSE at
baseline and total costs prior to baseline (Table 5,
Table 3 Mean unadjusted costs (£, 2013/14 prices) of trial medication, hospital care, community-based health and social care and primary care
Donepezil alone Placebo Memantine alone Donepezil plus memantine
Mean (SD) Mean (SD) Mean (SD) Mean (SD)
Pre-baseline (13weeks)—N 73 72 74 72
Hospital care 1516 (5289) 489 (2419) 327 (1037) 398 (1134)
Community-based care 864 (2205) 925 (2852) 721 (2019) 647 (1932)
Total cost 2380 (5977) 1414 (3972) 1048 (2322) 1045 (2187)
Weeks 1–6—N 72 71 73 68
Trial medication 3 1 4 5
Hospital care 149 (643) 246 (1163) 254 (1012) 93 (394)
Community-based care 248 (687) 242 (667) 149 (265) 221 (451)
Total cost 401 (939) 490 (1445) 414 (1122) 326 (695)
Weeks 7–30—N 63 60 60 63
Trial medication 10 0 12 22
Hospital care 1178 (4606) 1747 (4812) 764 (2512) 792 (1852)
Community-based care 1396 (2607) 1709 (5877) 1121 (2525) 1556 (4222)
Total cost 2584 (5086) 3456 (7919) 1973 (3397) 2445 (4570)
Weeks 31–52—N 54 55 51 58
Trial medication 9 0 11 20
Hospital care 940 (2928) 597 (1729) 829 (2530) 758 (2323)
Community-based care 2062 (3713) 3850 (17 929) 2124 (3854) 2069 (3547)
Total cost 3011 (4493) 4447 (17 944) 3033 (4580) 2915 (4365)
Weeks 1–52—N 53 55 51 56
Total health and social care costs 5418 (7464) 7964 (23 707) 4864 (7416) 5892 (8607)
Table 4 Mean unadjusted costs (£, 2013/14 prices) of health and social care and unpaid carer support, and total societal costs
Donepezil alone Placebo Memantine alone Donepezil plus memantine
Mean (SD) Mean (SD) Mean (SD) Mean (SD)
Pre-baseline (13weeks)—N 73 72 74 72
Health and social care 2380 (5977) 1414 (3972) 1048 (2322) 1045 (2187)
Unpaid care 4397 (7844) 2842 (5725) 4217 (6470) 5457 (7802)
Total societal cost 6777 (10 351) 4256 (6737) 5266 (6734) 6502 (7959)
Weeks 1–6—N 72 71 73 68
Health and social care 401 (939) 490 (1445) 406 (1122) 319 (695)
Unpaid care 1257 (2144) 793 (1425) 1043 (1616) 1228 (2533)
Total societal cost 1658 (2319) 1283 (1888) 1449 (1846) 1547 (2613)
Weeks 7–30—N 62 58 60 62
Health and social care 2178 (3967) 3222 (7733) 1898 (3397) 2311 (4583)
Unpaid care 4649 (8366) 2779 (5586) 4649 (6618) 4876 (5808)
Total societal cost 6828 (9254) 6001 (9167) 6547 (7634) 7186 (7922)
Weeks 31–52—N 47 41 43 52
Health and social care 2870 (4202) 5603 (20 703) 3460 (4832) 2978 (4508)
Unpaid care 5385 (7341) 4659 (7312) 7111 (11 641) 3978 (5905)
Total societal cost 8256 (7725) 10 262 (22 558) 10 640 (12 556) 7024 (7844)
Weeks 1–52—N 46 41 43 50
Health and social care 5530 (7592) 8531 (27 015) 5610 (7855) 6102 (8943)
Unpaid care 11 160 (15 035) 8884 (13 182) 14 359 (17 968) 9956 (11 815)
Total societal cost 16 690 (15 846) 17 415 (29 871) 19 969 (19 186) 16 058 (15 636)
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top rows). There were no signiﬁcant differences in
health and social care costs or societal costs in any of
the treatment comparisons.
Cost-effectiveness analysis: health and social care
perspective
Incremental cost-effectiveness ratios (ICERs) for each
outcome measure (BADLS, sMMSE, QALYs) were
computed from a health and social care perspective
(Table 5).
Patients continuing on donepezil had slightly lower
but not signiﬁcantly different costs than patients who
discontinued donepezil. Given that donepezil continu-
ation was associated with better outcomes than discon-
tinuation, donepezil thus dominates discontinuation.
CEACs allow us to summarise uncertainty in the
Table 5 Mean adjusted cost differences, incremental costs and outcomes, and cost-effectiveness ratios for each of the three treatment comparisons over
weeks 1–52
Mean difference* (95% CI)
Donepezil continuation
versus donepezil
discontinuation
Memantine versus
memantine placebo
Donepezil and memantine
combined versus
donepezil alone
Mean adjusted cost differences
(component and total) (£, 2013/14 prices)
Medication costs 20 26 46
Hospital care costs 63 (1236 to 1110) 594 (1768 to 580) 21 (1761 to 1719)
Community-based care costs 196 (3230 to 2839) 1288 (4465 to 1889) 93 (1815 to 2001)
Unpaid care costs 2037 (4385 to 311) 468 (2467 to 1531) 1875 (4309 to 559)
Total health and social care costs 389 (3600 to 2822) 1409 (4912 to 2094) 599 (2240 to 3438)
Total societal costs 2669 (7262 to 1923) 1457 (6330 to 3416) 331 (4641 to 3979)
Health and social care perspective:
incremental costs and effects*,
mean (95% CI)
Costs 389 (3600 to 2822) 1409 (4912 to 2094) 599 (2240 to 3438)
BADLS score 3.0 (0.7 to 5.2) 1.9 (0.4 to 4.1) 0.8 (3.5 to 5.2)
sMMSE score 1.7 (0.6 to 2.7) 0.9 (0.1 to 1.9) 0.1 (1.5 to 1.6)
QALY (EQ-5D) 0.11 (0.03 to 0.19) 0.07 (0.01 to 0.16) 0.03 (0.10 to 0.16)
Health and social care perspective:
incremental cost-effectiveness ratios*
(£, 2013/2014 prices)
… for BADLS Donepezil dominant Memantine dominant 749
… for sMMSE Donepezil dominant Memantine dominant 5990
… for QALY Donepezil dominant Memantine dominant 19 967
Societal perspective: incremental costs
and effects*, mean (95% CI)
Costs 2669 (7262 to 1923) 1457 (6330 to 3416) 331 (4641 to 3979)
BADLS score 3.0 (0.7 to 5.3) 1.2 (1.2 to 3.5) 1.1 (2.5 to 4.7)
sMMSE score 1.5 (0.4 to 2.7) 0.6 (0.6 to 1.7) 0.3 (1.8 to 1.1)
QALY (EQ-5D) 0.09 (0.00 to 0.19) 0.02 (0.08 to 0.12) 0.01 (0.13 to 0.16)
Societal perspective: incremental
cost-effectiveness ratios*
(£, 2013/2014 prices)
… for BADLS Donepezil dominant Memantine dominant 301
… for sMMSE Donepezil dominant Memantine dominant Donepezil dominant
… for QALY Donepezil dominant Memantine dominant 33 100
*Adjusted for centre, age, duration on donepezil, SMMSE score prior to randomisation and total costs at baseline.
**Higher scores indicate better outcomes on all measures
Figure 1 Cost-effectiveness acceptability curve: donepezil continua-
tion versus discontinuation; health and social care perspective, with ef-
fectiveness measured in QALYs.
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estimates. The CEAC when outcome is measured by
QALY gain (Figure 1) shows that the probability that
donepezil continuation would be seen as more cost-
effective than discontinuation is 93% at the £20000
threshold associated with NICE recommendations,
and 96% at the £30000 threshold (NICE, 2008).
For the second treatment comparison, patients
treated with memantine (with or without donepezil
continuation) had slightly lower but not statistically
signiﬁcantly different costs than patients treated with
memantine placebo (with or without donepezil
continuation), whilst clinical outcomes were close to
being statistically signiﬁcantly better (Table 5).
Memantine dominates memantine placebo from a
health and social care perspective, and the CEAC
when outcome is measured by QALY gain suggests
that the probability of memantine being more
cost-effective than memantine placebo is 92% at the
£20000 NICE threshold and 95% at the £30000
threshold (Figure 2).
The cost-effectiveness analyses for the third com-
parison show that donepezil–memantine combined
had slightly higher adjusted health and social care costs
compared to donepezil alone, although the difference
was not statistically signiﬁcant. Cost per QALY gained
was £19967 (Table 5). An alternative way to summa-
rise results for the other two outcome measures is to
calculate average cost of achieving a minimum
clinically important difference; for BADLS the annual
cost of achieving a 3.5-point difference is £2622, and
for sMMSE the annual cost of achieving a 1.4-point
difference is £8386. The CEAC with QALY as outcome
shows that the probability that donepezil–memantine
combined would be seen as more cost-effective
than donepezil alone is only 50% at the £20000
NICE threshold and 55% at the £30000 threshold
(Figure 3). For BADLS and sMMSE, the CEACs again
suggest low probabilities that donepezil–memantine
combined would be seen as more cost-effective than
donepezil alone, even at high willingness-to-pay values
(Figure 3).
Cost-effectiveness analysis: societal perspective
We repeated the analyses from a societal perspective
(Table 5). Outcome differences between treatments
differ slightly between the rows in Table 5 because of
the smaller sample with a societal perspective.
Donepezil continuation dominates donepezil dis-
continuation: better clinical outcomes and a reason-
able, if not signiﬁcant, societal cost advantage make
donepezil continuation the more cost-effective option.
Patients treated with memantine (with or without
donepezil continuation) had slightly lower but not
signiﬁcantly different societal costs than patients
treated with memantine placebo (with or without
donepezil continuation), whilst clinical outcomes were
not statistically signiﬁcantly different. The CEACs (not
shown) suggest reasonably high probabilities that
memantine would be seen as more cost-effective than
memantine placebo when considering cognitive func-
tioning (sMMSE, probabilities around 80%) or
health-related quality of life (QALY, probabilities
around 73%) but low probabilities (below 20%) when
considering BADLS.
Figure 2 Cost-effectiveness acceptability curve: memantine versus
memantine placebo; health and social care perspective, with effective-
ness measured in QALYs.
Figure 3 Cost-effectiveness acceptability curves: donepezil and
memantine versus donepezil only; health and social care perspective,
with effectiveness measured in QALYs, BADLS and MMSE.
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In the third analysis, costs and outcomes were not
observably different between donepezil alone and
donepezil–memantine combined: cost and clinical
outcome differences were tiny and not statistically sig-
niﬁcant. The probability that donepezil–memantine
combined would be seen as more cost-effective than
donepezil alone is modest (e.g. below 60% for all
willingness-to-pay values for QALYs).
Discussion
Based on a double-blind, placebo-controlled trial of
patients with moderate or severe AD already treated
with donepezil, we found that continuation of
donepezil treatment for a further 52weeks was more
cost-effective than discontinuation. Donepezil's cost-
effectiveness was demonstrated regardless of whether
outcomes were measured in terms of improvements
in cognitive impairment, functional impairment or
health-related quality of life, and whether costs were
measured just for the health and social care system
or for society as a whole.
Starting memantine treatment was also more
cost-effective than donepezil discontinuation from a
health and social care perspective by reference to all
three outcome measures, and (though less strongly)
was cost-effective from a societal perspective when
considering cognition and health-related quality of
life, but not when looking at functioning in activities
of daily living.
In contrast, donepezil–memantine combined is not
more cost-effective than donepezil alone by reference
to NICE thresholds for QALY gains, and the economic
case also looks weak when considering the other two
outcomes that we analysed (BADLS and MMSE).
Previous studies
AChE inhibitors (such as donepezil) and memantine
for the treatment of AD have been most frequently
investigated for patients with mild-to-moderate symp-
toms. In moderate-to-severe AD (Feldman et al., 2001;
Tariot et al., 2001) and severe AD (Fedldman et al.,
2005; Winblad et al., 2006) AChE inhibitors are
associated with modest improvements in cognition,
function and clinical global impression. There is
evidence that memantine is effective and cost-saving
in moderate and severe AD (Areosa et al., 2005;
Wimo et al., 2003), but it is not clear whether
memantine in combination with an AChE inhibitor
confers additional clinical beneﬁts (Tariot et al., 2004;
Porsteinsson et al., 2008). However, there is little
evidence to guide decisions regarding treatment con-
tinuation when symptoms become severe and patients
are still living at home.
There is even less evidence on cost-effectiveness.
Few economic evaluations of Alzheimer's medications
have been conducted within randomised controlled
trials, although numerous studies have employed sim-
ulation models (Bond et al., 2012; Knapp et al., 2012).
For donepezil, the only trial for patients with
moderate-to-severe AD with an economic evaluation
found no cost difference compared to placebo over
24weeks from a health system perspective and modest
savings (CDN$332) from a societal perspective
(Fedlman et al., 2001). For memantine, only model-
ling studies have been reported. For patients with
mild-to-moderate dementia, AChE inhibitors enhance
the effects of maintenance cognitive stimulation
therapy and improve its cost-effectiveness (D'Amico
et al., 2015).
Post-hoc analyses of data from DOMINO-AD
showed that discontinuation of donepezil increased
the risk of nursing home placement during the 52-
week trial period, although made no difference to this
risk over the subsequent 4 years (Howard et al., 2015).
Nursing home admissions account for a relatively
small part of the overall cost of AD, but delaying ad-
mission can substantially reduce service-related costs
for people with more severe dementia (Knapp et al.,
2016), even if it also risks increasing (prolonging)
costs associated with unpaid care. We found that
donepezil continuation was cost-effective even when
unpaid care costs were included.
The systematic review that informed the most re-
cent NICE Guidance [UPDATE] on use of AD drugs
identiﬁed very few trials with relevant data. The eco-
nomic model found a probability of only 38% that
memantine would be cost-effective at a willingness-
to-pay of £30000 per QALY (Bond et al., 2012), which
is a lot lower than our ﬁnding here (94%). Our data
therefore add to, and potentially change, the evidence
base on the cost-effectiveness of pharmacotherapy for
people with moderate/severe AD by suggesting that
both donepezil and memantine are more cost-
effective, when prescribed singly, than donepezil
discontinuation.
Limitations and strengths
DOMINO-AD was unusual in evaluating medica-
tions for patients with more severe cognitive symp-
toms than has been common previously,
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speciﬁcally recruiting participants reaching the
moderate-to-severe transition point. The study pe-
riod of 52weeks was unusually lengthy. The trial
was publicly funded (MRC, Alzheimer's Society),
and conducted independently. Both medications
were covered by patent at the time of the trial, but
are now both generic.
The trial failed to recruit its target number of par-
ticipants (410). This did not affect the power to detect
signiﬁcant differences on the co-primary outcomes
(cognition and function) between donepezil and
memantine and their respective placebos, but may
have contributed to failure to demonstrate signiﬁcant
cognitive or functional beneﬁts of donepezil–
memantine combined over donepezil alone. The
factorial design of the trial, however, allowed us to
demonstrate the individual beneﬁts of donepezil and
memantine regardless of whether medications were
taken alone or combined.
Estimating carer support costs is difﬁcult: it is hard
to measure time spent supporting someone with AD
that is appropriately counted as ‘care’, and hard to at-
tach an appropriate cost to that time. These common
uncertainties in economic evaluation do not, of
course, affect analyses from a health and social care
perspective. We could not calculate carer costs for
some patients, reducing sample size slightly for analy-
ses from a societal perspective.
Policy and practice implications
The independently conducted DOMINO-AD trial of-
fers new evidence on pharmacotherapy for AD pa-
tients who have progressed to the severe stage of
their illness. The results have relevance for both clini-
cal decision-making (including decisions taken by
health technology assessment bodies such as NICE)
and for commissioning, given our ﬁndings on cost-
effectiveness. For example, NICE guidelines can only
recommend the use of a medication within its licensed
indication. AChE inhibitors are not currently licensed
in England and Wales for the treatment of severe
AD, but only for mild-to-moderate AD. Memantine
is recommended for treatment of moderate or
severe AD (National Institute for Health and Care
Excellence 2016).
The trial suggests a strong case—not only on clini-
cal grounds but also on economic grounds—for
patients who have been successfully treated with
donepzil at the mild-to-moderate stages but who have
now progressed to more severe disease either continu-
ing with donepezil or switching to memantine.
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